# Phase 2 Graft vs Host Disease trials recruiting: 28 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 28 trials in phase 2 for Graft vs Host Disease that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Graft vs Host Disease trials: 28 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/graft-vs-host-disease

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 28
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 8, 2026 | NCT07808112 | CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell... | Medical College of Wisconsin | Phase 2 | Not yet recruiting | Graft -Versus-host-disease | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808112) |
| July 16, 2026 | NCT07708987 | Study of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease. | Tata Memorial Centre | Phase 2 | Recruiting | Hematological Malignancy, GVHD - Graft-Versus-Host Disease, Steriod Refractory | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708987) |
| May 26, 2026 | NCT07606703 | A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCT | Sponsor not shown (see the record) | Phase 2 | Recruiting | Chronic Graft-Versus-Host Disease, Graft vs Host Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07606703) |
| May 7, 2026 | NCT07572669 | Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Recruiting | Steroid-Refractory Acute Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease, Graft-Versus-Host Disease... | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572669) |
| May 6, 2026 | NCT07570745 | Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 2 | Recruiting | Graft-Versus-Host Disease(GVHD), Bone Marrow Transplantation | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570745) |
| May 5, 2026 | NCT07566377 | Cord Blood Transplantation in Children and Young Adults With Blood Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin... | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566377) |
| April 3, 2026 | NCT07509749 | Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease) | Sponsor not shown (see the record) | Phase 2 | Recruiting | GVHD, Acute, Stem Cell Transplant Complications | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509749) |
| January 23, 2026 | NCT07364617 | Fecal Microbiota Transplantation for Steroid-Refractory Acute GI GVHD | Chang Gung Memorial Hospital | Phase 2 | Recruiting | Graft vs Host Disease | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07364617) |
| January 22, 2026 | NCT07359859 | A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell... | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Hematologic Malignancies | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07359859) |
| January 21, 2026 | NCT07356245 | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | Ohio State University Comprehensive Cancer Center | Phase 2 | Recruiting | T-cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-Cell, Peripheral T Cell Lymphoma, T-cell Prolymphocytic... | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07356245) |
| November 24, 2025 | NCT07246031 | BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation | BioPhoenix Co., Ltd. | Phase 2 | Recruiting | Graft -Versus-host-disease, aGVHD, Haploidentical Stem Cell Transplantation, cGVHD | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07246031) |
| October 14, 2025 | NCT07216443 | Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic... | Orca Biosystems, Inc. | Phase 2 | Recruiting | Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07216443) |
| August 12, 2025 | NCT07118254 | A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN... | Lubris Bio Pty Ltd | Phase 2 | Recruiting | Ocular Graft Versus Host Disease | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07118254) |
| June 5, 2025 | NCT07006506 | A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Graft Versus Host Disease, Graft Vs Host Disease, Hematologic Malignancy | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07006506) |
| April 13, 2025 | NCT06926595 | Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention | Milton S. Hershey Medical Center | Phase 2 | Recruiting | Graft-versus-Host Disease (GVHD), Hematologic Malignancies, Allogeneic Stem Cell Transplantation | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06926595) |
| April 1, 2025 | NCT06905834 | Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to... | Instituto de Investigación Biomédica de Salamanca | Phase 2 | Not yet recruiting | Dry Eye Disease (DED), Graft-Versus-Host Disease(GVHD) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06905834) |
| February 7, 2025 | NCT06815003 | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients... | City of Hope Medical Center | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease... | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06815003) |
| January 29, 2025 | NCT06799195 | Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation | University of Nebraska | Phase 2 | Recruiting | Hematological Malignancies, Graft-versus-Host Disease (GVHD) | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06799195) |
| January 1, 2025 | NCT06756061 | Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients... | Sponsor not shown (see the record) | Phase 2 | Recruiting | GVHD - Graft-Versus-Host Disease, Neoplasms, Haematopoietic Stem Cell Transplantation | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06756061) |
| October 4, 2024 | NCT06626737 | Dapagliflozin in Allo-HCT for aGVHD | The First Affiliated Hospital of Soochow University | Phase 2 | Recruiting | Graft-versus-host Disease (GVHD) | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06626737) |
| October 1, 2024 | NCT06619561 | A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) | Deciphera Pharmaceuticals, LLC | Phase 2 | Recruiting | Chronic Graft-Versus-Host Disease (cGVHD) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06619561) |
| June 10, 2024 | NCT06450925 | Vitamin A Supplementation in Allogeneic Stem Cell Transplantation. | Children's Hospital Medical Center, Cincinnati | Phase 2 | Recruiting | Graft Vs Host Disease, Vitamin A Deficiency, Vitamin D Deficiency | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06450925) |
| February 12, 2024 | NCT06252870 | Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients... | Nantes University Hospital | Phase 2 | Recruiting | Graft Versus Host Disease, Hematologic Malignancy | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06252870) |
| January 9, 2023 | NCT05675930 | A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Graft-Versus-Host Disease, GVHD, Undefined | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05675930) |
| June 23, 2021 | NCT04935684 | Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation | University Hospital, Clermont-Ferrand | Phase 2 | Recruiting | Acute Leukemia in Remission, Myelodysplastic Syndromes, Myeloproliferative Syndrome, Hodgkin Lymphoma, Lymphoma... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04935684) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Memorial Sloan Kettering Cancer Center | 4 |
| Medical College of Wisconsin | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| City of Hope Medical Center | 1 |
| Boston Children's Hospital | 1 |
| Ohio State University Comprehensive Cancer Center | 1 |
| Chang Gung Memorial Hospital | 1 |
| Tata Memorial Centre | 1 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| University Hospital, Clermont-Ferrand | 1 |
| Milton S. Hershey Medical Center | 1 |
| Instituto de Investigación Biomédica de Salamanca | 1 |
| University of Liege | 1 |
| Lubris Bio Pty Ltd | 1 |
| Orca Biosystems, Inc. | 1 |
| BioPhoenix Co., Ltd. | 1 |
| University of Nebraska | 1 |
| Nantes University Hospital | 1 |
| [Deciphera Pharmaceuticals, LLC](https://specstream.ai/data/clinical-trials/company/deciphera-pharmaceuticals-llc) | 1 |
| The First Affiliated Hospital of Soochow University | 1 |
| [Syndax Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/syndax-pharmaceuticals) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 14 |
| China | 6 |
| France | 3 |
| Taiwan | 2 |
| Belgium | 2 |
| South Korea | 2 |
| Australia | 2 |
| India | 1 |
| Canada | 1 |
| Germany | 1 |
| Greece | 1 |
| Israel | 1 |
| Italy | 1 |
| Poland | 1 |
| Portugal | 1 |
| Singapore | 1 |
| Spain | 1 |
| United Kingdom | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Latin American restaurants in the United States](https://specstream.ai/data/businesses/latin-american-restaurants/united-states)
- [Tobacco companies in the United States](https://specstream.ai/data/businesses/tobacco-companies/united-states)
- [Debt relief companies in the United States](https://specstream.ai/data/businesses/debt-relief-companies/united-states)
- [Moroccan restaurants in the United States](https://specstream.ai/data/businesses/moroccan-restaurants/united-states)
- [Whiskey bars in the United States](https://specstream.ai/data/businesses/whiskey-bars/united-states)
- [Energy management companies in the United States](https://specstream.ai/data/businesses/energy-management-companies/united-states)
